Overview of Class Action Lawsuits
There are significant class action lawsuits currently filed against DexCom, Inc. (NASDAQ: DXCM) and CarMax, Inc. (NYSE: KMX), as announced by a leading law firm focused on investor rights, Bragar Eagel & Squire, P.C. These lawsuits emphasize the importance for investors to take action promptly, understanding their rights in the context of recent allegations against these companies.
Details on DexCom, Inc. Class Action
DexCom, Inc. (NASDAQ: DXCM) faces serious allegations in connection with its products regarding glucose monitoring systems. The complaint underscores a class period from January 8, 2024, to September 17, 2025. During this timeframe, it has been alleged that DexCom provided false and misleading statements about the safety and compliance of its G6 and G7 devices.
Key Allegations
Investors are reminded that throughout the specified class period, DexCom reportedly made several misleading claims about its technology's reliability. The firm stated that the devices were subject to unauthorized changes that compromised their reliability, potentially endangering the health of users relying on them for accurate glucose readings.
Important Dates
The lead plaintiff deadline for this case is December 26, 2025. Vigilant investors are encouraged to act before this date to ensure their participation in the proceedings.
Details on CarMax, Inc. Class Action
CarMax, Inc. (NYSE: KMX) is another entity facing class action litigation. The class action against CarMax covers a period from June 20, 2025, to September 24, 2025. Allegations suggest that the company misrepresented its growth potential, as the initial growth was reportedly a temporary reaction to external market conditions rather than genuine growth metrics.
Understanding CarMax's Class Allegations
Specific claims indicate that CarMax exaggerated its financial health and business prospects, misleading investors. Once the true nature of its growth became evident, investors reportedly faced significant financial losses.
Important Deadlines for CarMax
For those looking to join the CarMax lawsuit, the lead plaintiff deadline is set for January 2, 2026. It's vital for potential claimants to take timely action to protect their interests.
How to Participate in These Lawsuits
Investors in both DexCom and CarMax should consider seeking counsel from experienced legal professionals for guidance on their rights and options. Those wishing to join these actions can contact Bragar Eagel & Squire, P.C. for further assistance and information.
About Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is a highly regarded law firm dedicated to the representation of individual and institutional investors. Their practice spans various legal areas, including securities, derivative litigation, and consumer protection. The firm prides itself on its ability to navigate complex legal proceedings within both federal and state courts.
Contact Information
If investors have inquiries regarding these lawsuits or require further information, they can reach out to Brandon Walker, Esq. or Melissa Fortunato, Esq. at:
Bragar Eagel & Squire, P.C.
Phone: (212) 355-4648
Email: investigations@bespc.com
Website: www.bespc.com
Frequently Asked Questions
What is the purpose of the class action lawsuits?
The class action lawsuits aim to provide a way for investors who suffered losses due to misleading statements by DexCom and CarMax to seek compensation.
How can I join the class action lawsuits?
Investors should contact the law firm handling the cases, Bragar Eagel & Squire, P.C., for guidance on joining the lawsuits.
What are the deadlines associated with these lawsuits?
For DexCom, the lead plaintiff deadline is December 26, 2025, and for CarMax, it’s January 2, 2026.
What allegations are made against DexCom?
The allegations include false claims regarding the safety and reliability of its G6 and G7 glucose monitoring systems.
Where can I find more information?
For further details about the lawsuits, investors can visit the Bragar Eagel & Squire, P.C. website or contact them directly.
